HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Arthur He has reiterated a 'Buy' rating on Poseida Therapeutics (NASDAQ:PSTX) and maintained a $15 price target.
August 08, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics (NASDAQ:PSTX) has had its 'Buy' rating reiterated by HC Wainwright & Co., with a maintained price target of $15.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $15 also indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100